Ultragenyx Pharmaceutical (MEX:RARE) Accounts Payable: MXN757 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RARE Ultragenyx Pharmaceutical Inc MEX:RARE
66 GF Score
Price MXN1,150.56
GF Value MXN1,699.44
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Accounts Payable?

Ultragenyx Pharmaceutical MEX:RARE 66 Accounts Payable is MXN757 Mil as of Mar. 2026. GuruFocus rates MEX:RARE with a GF Score™ of 66/100 and a GF Value™ of MXN1,699.44. The stock has 5 warning signs investors should review.

Ultragenyx Pharmaceutical's Accounts Payable for the quarter that ended in Mar. 2026 was MXN757 Mil.

Ultragenyx Pharmaceutical's quarterly Accounts Payable declined from Sep. 2025 (MXN744 Mil) to Dec. 2025 (MXN558 Mil) but then increased from Dec. 2025 (MXN558 Mil) to Mar. 2026 (MXN757 Mil).

Ultragenyx Pharmaceutical's annual Accounts Payable increased from Dec. 2023 (MXN715 Mil) to Dec. 2024 (MXN813 Mil) but then declined from Dec. 2024 (MXN813 Mil) to Dec. 2025 (MXN558 Mil).

Ultragenyx Pharmaceutical Accounts Payable Related Terms

Ultragenyx Pharmaceutical Accounts Payable Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Accounts Payable Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 351.57 843.67 714.85 813.37 558.18

Ultragenyx Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 970.74 644.75 744.28 558.18 757.37
MEX:RARE
66GF Score
Ultragenyx Pharmaceutical Inc MEX:RARE
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of MXN757 Mil mean?
Ultragenyx Pharmaceutical (MEX:RARE) has a Accounts Payable of MXN757 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Accounts Payable too high?
Ultragenyx Pharmaceutical's current Accounts Payable is MXN757 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Accounts Payable compare to VERA and IRON?
Ultragenyx Pharmaceutical's Accounts Payable of MXN757 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Accounts Payable is MXN757 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Accounts Payable of MXN757 Mil. The stock's GF Value™ is MXN1,699.44, compared to a current price of MXN1,150.56 — trading 32.3% below its estimated fair value. The current Accounts Payable is MXN757 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Accounts Payable is MXN757 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,150.56 is trading 32.3% below its estimated GF Value™ of MXN1,699.44.

Key valuation signals for MEX:RARE:

  • Accounts Payable: MXN757 Mil
  • GF Value™: MXN1,699.44 vs. price of MXN1,150.56 (32.3% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
66GF Score

Get the complete analysis for MEX:RARE

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.56
Price
MXN1,699.44
GF Value